Market revenue in 2023 | USD 28.8 million |
Market revenue in 2030 | USD 66.4 million |
Growth rate | 12.7% (CAGR from 2023 to 2030) |
Largest segment | Ctc detection & enrichment methods |
Fastest growing segment | CTC Analysis |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis |
Key market players worldwide | Qiagen NV, Bio-Techne Corp, Praxis Precision Medicines Inc Ordinary Shares, Aviva PLC, Biocept Inc, Neurocrine Biosciences Inc, Greiner Bio-One, Miltenyi Biotec, Icon PLC, Ecolab Inc, Arcus Biosciences Inc, Epic Corp, Screen Holdings Co Ltd, Menarini Group, Vtex Ordinary Shares - Class A, Sysmex Corp, STEMCELL Technologies |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to circulating tumor cells market will help companies and investors design strategic landscapes.
Ctc detection & enrichment methods was the largest segment with a revenue share of 66.67% in 2023. Horizon Databook has segmented the Argentina circulating tumor cells market based on ctc detection & enrichment methods, ctc direct detection methods, ctc analysis covering the revenue growth of each sub-segment from 2018 to 2030.
The increasing prevalence of chronic diseases and rising government expenditure in the healthcare sector of the country are anticipated to drive the generic pharmaceuticals market. An article suggests that around USD 414.2 million, USD 233 million, and USD 139.8 million were invested in universal health care, accident & emergency, and solidarity redistribution fund, respectively, in 2019.
The geriatric population accounted for 11.2% of the overall population in Argentina in 2019. The geriatric population is responsible for increasing chronic diseases in the country. The population lacks proper healthcare coverage, and over 36% of the population does not have formal healthcare coverage & is dependent the on public healthcare system.
Furthermore, in July 2020, Cámara Industrial de Laboratorios Farmacéuticos Argentinos (CILFA) joined the International Generic and Biosimilar Medicines Association as a new associate member. CILFA is a group of 38 biosimilar and generic drug manufacturers, with 68% share of the Argentinian market in 2019.
Horizon Databook provides a detailed overview of country-level data and insights on the Argentina circulating tumor cells market , including forecasts for subscribers. This country databook contains high-level insights into Argentina circulating tumor cells market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account